Beta Bionics, Inc.
24.28+0.53 (+2.23%)
Oct 28, 4:00:02 PM EDT · NasdaqGM · BBNX · USD
Key Stats
Market Cap
1.06BP/E (TTM)
-Basic EPS (TTM)
-1.73Dividend Yield
0%Recent Filings
10-Q
8-K
10-Q
Q2 FY2025 results
Beta Bionics posted Q2 FY2025 net sales of $23.2M, up 54% y/y from $15.0M, with single-use products now 41% of revenue versus 21% last year, driven by an installed base of 24,085 users. Gross margin held steady at 54%, while operating loss widened to $19.9M from $11.8M y/y amid 74% sales and marketing growth to support expansion. Cash and equivalents stood at $35.1M, bolstered by $280.9M in short- and long-term investments post-IPO; free cash flow not disclosed in the 10-Q. The IPO closed in January 2025, converting all preferred stock and warrants to common shares. Competition from larger rivals with deeper resources remains a key risk.
8-K
Q2 sales soar 54%
Beta Bionics reported Q2 2025 net sales of $23.2 million, surging 54% from $15.0 million in Q2 2024, fueled by 4,934 new patient starts—up 57%—and a 200% jump in installed base to 24,085 users. The PBP channel exploded 498% to $4.6 million, with high 20s percentage of starts reimbursed there, while gross margin edged up to 53.8%. Momentum builds. Company raised full-year revenue guidance to $88–$93 million, targeting 25–28% PBP reimbursement, but net loss widened to $16.9 million amid rising operating costs.
8-K
iLet data boosts glycemic control
Beta Bionics unveiled two-year real-world data on its iLet Bionic Pancreas, showing 14,952 users slashing average HbA1c from 8.9% to 7.3% GMI, with over 84% hitting ADA hypoglycemia targets. Improvements held steady across prior therapies like MDI and hybrid-closed loops, plus endocrinology and primary care settings. The algorithm stabilizes in two days. Yet real-world outcomes may diverge from trials.
ABT
Abbott Laboratories
126.61-0.57
BDX
Becton, Dickinson and Company
184.21-2.83
BMRA
Biomerica, Inc.
2.93-0.03
BSX
Boston Scientific Corporation
100.97-1.46
DXCM
DexCom, Inc.
69.23-1.40
MDT
Medtronic plc.
93.23-0.90
MODD
Modular Medical, Inc.
0.54-0.01
PODD
Insulet Corporation
324.34-1.46
SENS
Senseonics Holdings, Inc.
7.20-0.24
TNDM
Tandem Diabetes Care, Inc.
15.10+0.16